Cargando…

Multiple myeloma: challenges with deciding the optimal sequencing strategy

Detalles Bibliográficos
Autores principales:	Walia, Anushka, Haslam, Alyson, Tuia, Jordan, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350499/ https://www.ncbi.nlm.nih.gov/pubmed/37465528 http://dx.doi.org/10.3389/fphar.2023.1231720

Ejemplares similares

Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals
por: Haslam, Alyson, et al.
Publicado: (2023)

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
por: Haslam, Alyson, et al.
Publicado: (2023)

Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals
por: Buck, Eva, et al.
Publicado: (2023)

Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity
por: Olivier, Timothée, et al.
Publicado: (2023)

Extended anticoagulation for VTE: what evidence justifies it?
por: Walia, Anushka, et al.
Publicado: (2023)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Comparability of Control and Comparison Groups in Studies Assessing Long COVID
por: Haslam, Alyson, et al.
Publicado: (2023)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
por: Haslam, Alyson, et al.
Publicado: (2019)

Characteristics of Facebook’s third-party medical fact checkers
por: Haslam, Alyson, et al.
Publicado: (2022)

Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
por: Walia, Anushka, et al.
Publicado: (2023)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Comprehensive elaboration of circular RNA in multiple myeloma
por: Zhu, Chunsheng, et al.
Publicado: (2022)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

SNPs in cytochrome P450 genes decide on the fate of individuals with genetic predisposition to Parkinson’s disease
por: Petkova-Kirova, Polina, et al.
Publicado: (2023)

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2021)

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
por: Olivier, Timothée, et al.
Publicado: (2023)

The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review
por: Bhatt, Anjali, et al.
Publicado: (2023)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

Medical Reversals in Family Practice: A Review
por: Haslam, Alyson, et al.
Publicado: (2020)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials
por: Olivier, Timothée, et al.
Publicado: (2022)

How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature
por: Haslam, Alyson, et al.
Publicado: (2022)

The frequency of assessment of progression in randomized oncology clinical trials
por: Haslam, Alyson, et al.
Publicado: (2021)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Analysis of the Metabolic Characteristics of Serum Samples in Patients With Multiple Myeloma
por: Du, Haiwei, et al.
Publicado: (2018)

Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Publicado: (2021)

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use
por: Prasad, Vinay, et al.
Publicado: (2023)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma
por: Silveira, Lívia Pena, et al.
Publicado: (2021)

Comprehensive analysis of ferroptosis-related genes in immune infiltration and prognosis in multiple myeloma
por: Wang, Quanqiang, et al.
Publicado: (2023)

Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis
por: Hou, Zhaomeng, et al.
Publicado: (2022)

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials
por: Ahmed, Nibras, et al.
Publicado: (2022)

Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy?
por: De Silva, T. Michael, et al.
Publicado: (2016)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
por: Cao, Yaohua, et al.
Publicado: (2021)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
por: Li, Qian, et al.
Publicado: (2018)

Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
por: Yu, Chao-Chao, et al.
Publicado: (2022)

Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients
por: Wang, Xi, et al.
Publicado: (2022)

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis
por: Banerjee, Titas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rtjqb488b3hagn3tgfdbdndqae